KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$5.90 USD
-0.16 (-2.64%)
Updated Aug 28, 2024 01:57 PM ET
After-Market: $5.96 +0.06 (1.02%) 7:40 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
KALA BIO, Inc. [KALA]
Reports for Purchase
Showing records 201 - 220 ( 367 total )
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
EYSUVIS/DED: FDA Accepted NDA for Review - Set PDUFA to October 30, 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Dry Eye Disease Resubmission Accepted; Reiterate Buy; Raising PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Underwhelming Competitor Data in Dry Eye Disease; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Q1; Cash Runway Covers Key Catalysts; DED NDA Acceptance Expected ~Late May
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Financial Results Reported; Reiterate Buy; Modulating PT Up to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Dry Eye Drug Resubmitted for Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
EYSUVIS/DED: NDA Resubmitted; We Expect NDA Acceptance for Review in July
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L